This company no longer operates independently (acquired, merged, or ceased operations). This profile is retained for reference.
Clinical-stage life-science company founded in 2013 focused on transforming psychedelics into medicines, with lead candidate ELE-Psilo, an IV psilocybin formulation for depression. In January 2022 it agreed to merge with Silver Spike Acquisition Corp. II (a SPAC) at a $446 million enterprise value to go public on Nasdaq, but the two parties mutually terminated the combination in June 2022 citing unfavorable market conditions. The company appears to have gone largely quiet after the failed merger.
Eleusis News 3 articles
- Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited
- Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp.
- LSU Health Foundation, New Orleans and Foundation Board of Directors Announce Strategic Investment to Support Prevention and Treatment of Inflammatory Eye Disease